We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

105 hedge funds and large institutions have $132M invested in VYNE Therapeutics in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.04% less ownership

Funds ownership: 0.7% → 0.66% (-0.04%)

1% less funds holding

Funds holding: 106 → 105 (-1)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

17% less capital invested

Capital invested by funds: $160M → $132M (-$28M)

Holders
105
Holders Change
-1
Holders Change %
-0.94%
% of All Funds
2.12%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
19
Increased
33
Reduced
25
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.64M
2
State Street
State Street
Massachusetts
+$749K
3
6CM
683 Capital Management
New York
+$679K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$594K
5
Northern Trust
Northern Trust
Illinois
+$442K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$2.95M
2
Millennium Management
Millennium Management
New York
-$2.16M
3
CCM
CAAS Capital Management
New York
-$2.05M
4
SI
Sofinnova Investments
California
-$1.26M
5
BBVA
Banco Bilbao Vizcaya Argentaria
Spain
-$1.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
TFA
76
Tobias Financial Advisors
Florida
$24K +$23.3K +200 New
Qube Research & Technologies (QRT)
77
Qube Research & Technologies (QRT)
United Kingdom
$22K +$21.7K +186 New
Legal & General Group
78
Legal & General Group
United Kingdom
$21K -$1.98K -17 -9%
RJFSA
79
Raymond James Financial Services Advisors
Florida
$21K +$20.8K +178 New
HSBC Holdings
80
HSBC Holdings
United Kingdom
$21K +$21.2K +182 New
KWMG
81
King Wealth Management Group
Florida
$19K – – –
TWA
82
TCI Wealth Advisors
Arizona
$19K +$467 +4 +3%
Principal Financial Group
83
Principal Financial Group
Iowa
$19K +$18.3K +157 New
EGM
84
Engineers Gate Manager
New York
$18K -$26.7K -229 -61%
CS
85
Credit Suisse
Switzerland
$18K -$5.83K -50 -25%
DTL
86
Dynamic Technology Lab
Singapore
$18K +$17.7K +152 New
AB
87
Amalgamated Bank
New York
$17K +$350 +3 +2%
NIM
88
NXG Investment Management
Texas
$17K +$16.3K +140 New
T. Rowe Price Associates
89
T. Rowe Price Associates
Maryland
$17K +$16.7K +143 New
AIP
90
Ameritas Investment Partners
Nebraska
$16K – – –
Citigroup
91
Citigroup
New York
$12K -$11.8K -101 -51%
Bank of Montreal
92
Bank of Montreal
Ontario, Canada
$12K -$7.47K -64 -41%
CSS
93
Cubist Systematic Strategies
Connecticut
$11K -$233 -2 -2%
Royal Bank of Canada
94
Royal Bank of Canada
Ontario, Canada
$8K -$700 -6 -8%
Ohio Public Employees Retirement System (OPERS)
95
Ohio Public Employees Retirement System (OPERS)
Ohio
$5K – – –
Osaic Holdings
96
Osaic Holdings
Arizona
$3K – – –
CB
97
CNB Bank
Pennsylvania
$2K – – –
APWA
98
Atlas Private Wealth Advisors
New Jersey
$1K – – –
CCM
99
Cribstone Capital Management
Maine
$1K – – –
Nisa Investment Advisors
100
Nisa Investment Advisors
Missouri
$1K – – –
1 2 3
4
5

VYNE Hedge Fund Activity: Q3 2020 in Review

105 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2020, worth a combined $132M — down 17% from $160M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of VYNE and 19 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 33 added.

The largest buyer was BlackRock, adding an estimated $2.64M. The largest seller was Vivo Capital, cutting an estimated $2.95M.

  • 105 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2020, down from 106 in Q2 2020.
  • Funds reported $132M of VYNE Therapeutics stock for Q3 2020, down 17% quarter-over-quarter.
  • 19 funds opened new VYNE Therapeutics positions in Q3 2020 and 20 closed out, a net change of -1 holder.
  • The largest VYNE Therapeutics buyer in Q3 2020 was BlackRock, an estimated $2.64M added.
  • The largest VYNE Therapeutics seller in Q3 2020 was Vivo Capital, an estimated $2.95M sold.

Based on aggregated 13F filings for Q3 2020.